These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31727945)

  • 1. Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine.
    Yenkoidiok-Douti L; Williams AE; Canepa GE; Molina-Cruz A; Barillas-Mury C
    Sci Rep; 2019 Nov; 9(1):16833. PubMed ID: 31727945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
    Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
    Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei.
    Yao G; Min H; Yu X; Liu F; Cui L; Cao Y
    Parasit Vectors; 2023 Nov; 16(1):403. PubMed ID: 37932796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of
    Kurtovic L; Wetzel D; Reiling L; Drew DR; Palmer C; Kouskousis B; Hanssen E; Wines BD; Hogarth PM; Suckow M; Jenzelewski V; Piontek M; Chan JA; Beeson JG
    Front Immunol; 2021; 12():641421. PubMed ID: 33815393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.
    Andersson AC; Resende M; Salanti A; Nielsen MA; Holst PJ
    Vaccine; 2017 Feb; 35(8):1140-1147. PubMed ID: 28131394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.
    Urakami A; Sakurai A; Ishikawa M; Yap ML; Flores-Garcia Y; Haseda Y; Aoshi T; Zavala FP; Rossmann MG; Kuno S; Ueno R; Akahata W
    Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response.
    Marini A; Zhou Y; Li Y; Taylor IJ; Leneghan DB; Jin J; Zaric M; Mekhaiel D; Long CA; Miura K; Biswas S
    Front Immunol; 2019; 10():2931. PubMed ID: 31921185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
    Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
    J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pfs47 as a Malaria Transmission-Blocking Vaccine Target.
    Molina-Cruz A; Barillas-Mury C
    Am J Trop Med Hyg; 2022 Jul; ():. PubMed ID: 35895390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
    Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
    Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe.
    Paul NH; Vengesai A; Mduluza T; Chipeta J; Midzi N; Bansal GP; Kumar N
    Acta Trop; 2016 Nov; 163():103-8. PubMed ID: 27491342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
    Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Yenkoidiok-Douti L; Canepa GE; Barletta ABF; Barillas-Mury C
    Front Microbiol; 2020; 11():1496. PubMed ID: 32719666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
    King LDW; Pulido D; Barrett JR; Davies H; Quinkert D; Lias AM; Silk SE; Pattinson DJ; Diouf A; Williams BG; McHugh K; Rodrigues A; Rigby CA; Strazza V; Suurbaar J; Rees-Spear C; Dabbs RA; Ishizuka AS; Zhou Y; Gupta G; Jin J; Li Y; Carnrot C; Minassian AM; Campeotto I; Fleishman SJ; Noe AR; MacGill RS; King CR; Birkett AJ; Soisson LA; Long CA; Miura K; Ashfield R; Skinner K; Howarth MR; Biswas S; Draper SJ
    Cell Rep Med; 2024 Jul; 5(7):101654. PubMed ID: 39019011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with virus-like particles conjugated to CIDRĪ±1 domain of Plasmodium falciparum erythrocyte membrane protein 1 induces inhibitory antibodies.
    Harmsen C; Turner L; Thrane S; Sander AF; Theander TG; Lavstsen T
    Malar J; 2020 Mar; 19(1):132. PubMed ID: 32228596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity.
    Chan JA; Wetzel D; Reiling L; Miura K; Drew DR; Gilson PR; Anderson DA; Richards JS; Long CA; Suckow M; Jenzelewski V; Tsuboi T; Boyle MJ; Piontek M; Beeson JG
    PLoS One; 2019; 14(9):e0221733. PubMed ID: 31504038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.
    Jones RM; Chichester JA; Mett V; Jaje J; Tottey S; Manceva S; Casta LJ; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Mett V; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    PLoS One; 2013; 8(11):e79538. PubMed ID: 24260245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.